ArticleCancers2017

Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients.

Susan Cedra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.